Correlation between iris-registered static and dynamic cyclotorsions with preoperative refractive astigmatism in PRK candidates

Purpose: To evaluate static and dynamic cyclotorsions during photorefractive keratotomy (PRK) surgery in refractive surgery candidates and their correlations with preoperative factors. Methods: This cross-sectional case series was performed in 138 eyes of 77 patients who underwent PRK surgery by Technolas 217z100. Iris registration was used to evaluate the degree of static and dynamic cyclotorsion. Wavefront measurements were performed in sitting position using Zywave (versions 3.1 and 3.2, Bausch & Lomb) Hartmann Shack aberrometer (Bausch & Lomb), and the cyclotorsion from upright to supine position was measured using iris image comparison. Dynamic cyclotorsions were measured by Advanced Cyclotorsional Eye Tracker (ACE) mounted on Excimer laser machine Technolas 217z100 during surgery. Results: The mean absolute static cyclotorsion that was captured in surgery time was 3.37 ± 2.38° (range, 0.00 to 11.30), and the mean absolute dynamic cyclotorsion was 2.54 ± 2.50° (range, 0.00 to 13.60). There was a significant correlation between dynamic cyclotorsions and static cyclotorsions (P < 0.001 and R = 0.704). There was a strong association between preoperative refractive astigmatism and range dynamic cyclotorsion. Total pulses (P = 0.009), ablation depth (P = 0.012), gender (P = 0.008) had significant correlations with cyclotorsional movements. Conclusion: The measurements of static and dynamic cyclotorsions are highly recommended for refractive surgery candidates with significant preoperative refractive astigmatism. Keywords: Cyclotorsions, Astigmatism, Refractive surger

Clinical management guidelines for Friedreich ataxia: best practice in rare diseases

Abstract Background Individuals with Friedreich ataxia (FRDA) can find it difficult to access specialized clinical care. To facilitate best practice in delivering healthcare for FRDA, clinical management guidelines (CMGs) were developed in 2014. However, the lack of high-certainty evidence and the inadequacy of accepted metrics to measure health status continues to present challenges in FRDA and other rare diseases. To overcome these challenges, the Grading of Recommendations Assessment and Evaluation (GRADE) framework for rare diseases developed by the RARE-Bestpractices Working Group was adopted to update the clinical guidelines for FRDA. This approach incorporates additional strategies to the GRADE framework to support the strength of recommendations, such as review of literature in similar conditions, the systematic collection of expert opinion and patient perceptions, and use of natural history data. Methods A panel representing international clinical experts, stakeholders and consumer groups provided oversight to guideline development within the GRADE framework. Invited expert authors generated the Patient, Intervention, Comparison, Outcome (PICO) questions to guide the literature search (2014 to June 2020). Evidence profiles in tandem with feedback from individuals living with FRDA, natural history registry data and expert clinical observations contributed to the final recommendations. Authors also developed best practice statements for clinical care points that were considered self-evident or were not amenable to the GRADE process. Results Seventy clinical experts contributed to fifteen topic-specific chapters with clinical recommendations and/or best practice statements. New topics since 2014 include emergency medicine, digital and assistive technologies and a stand-alone section on mental health. Evidence was evaluated according to GRADE criteria and 130 new recommendations and 95 best practice statements were generated. Discussion and conclusion Evidence-based CMGs are required to ensure the best clinical care for people with FRDA. Adopting the GRADE rare-disease framework enabled the development of higher quality CMGs for FRDA and allows individual topics to be updated as new evidence emerges. While the primary goal of these guidelines is better outcomes for people living with FRDA, the process of developing the guidelines may also help inform the development of clinical guidelines in other rare diseases.info:eu-repo/semantics/publishe